Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities

References

• Schorling DC, Becker J, Pechmann A, et al. Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2019;93:267–269.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, et al. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet. 1998;7(10):1531–1536.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16(3):265–269.
   PubMed Web of Science ®Google Scholar
• Ramos DM, d’Ydewalle C, Gabbeta V, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Ivest. 2019;129(11):4817–4831.
   Google Scholar
• Chaytow H, Huang YT, Gillingwater TH, et al. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018;75(21):3877–3894.
   PubMed Web of Science ®Google Scholar
• Lipnick SL, Agniel DM, Aggarwal R, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One. 2019;14(3):e0213680.
   PubMed Web of Science ®Google Scholar
• Nash LA, Burns JK, Chardon JW, et al. Spinal muscular atrophy: more than a disease of motor neurons? Curr Mol Med. 2016;16(9):779–792.
   PubMed Web of Science ®Google Scholar
• Martínez-Hernández R, Soler-Botija C, Also E, et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol. 2009;68;68(5)::474–81.
   PubMed Web of Science ®Google Scholar
• Goulet B, Kothary R, Parks RJ. At the “junction” of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Curr Mol Med. 2013;13(7):1160–1174.
   PubMed Web of Science ®Google Scholar
• Deguise MO, Pileggi C, Beauvais A, et al. A mouse model for spinal muscular atrophy provides insights into non-alcoholic fatty liver disease pathogenesis. bioRxiv. 2020;04:29.051938.
   Google Scholar
• Heier CR, Satta R, Lutz C, et al. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet. 2010;19(20):3906–3918.
   PubMed Web of Science ®Google Scholar
• Somers E, Lees RD, Hoban K, et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann Neurol. 2016;79(2):217230.
   Web of Science ®Google Scholar
• Hosseinibarkooie S, Peters M, Torres-Benito L, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet. 2016;99(3):647–665.
   PubMed Web of Science ®Google Scholar
• Oskoui M, Darras B, De Vivo D. Chapter 1, Spinal Muscular Atrophy: 125 years later on the verge of a cure. In: Sumner C, Paushkin S, Ko C, editors. Spinal muscular atrophy: disease mechanisms and therapy. London: Elsevier; 2017:1–18.
   Google Scholar
• Chabanon A, Seferian AM, Daron A, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One. 2018;13(7):e0201004.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orph J Rare Dis. 2021;16(1):47.
   PubMed Web of Science ®Google Scholar
• Annoussamy M, Seferian AM, Daron A, et al. NatHis-SMA study group. natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8(2):359–373.
   PubMed Web of Science ®Google Scholar
• Aragon‐Gawinska K, Daron A, Ulinici A, et al. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2020;62(3):310–314.
   PubMed Web of Science ®Google Scholar
• Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019;61(1):19–24.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153–1161.
   PubMed Web of Science ®Google Scholar
• Boemer F, Caberg JH, Dideberg V, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord. 2019;29(5):343–349.
   PubMed Web of Science ®Google Scholar
• Vill K, Kölbel H, Schwartz O, et al. One year of newborn screening for SMA - results of a german pilot project. J Neuromuscul Dis. 2019;6(4):503–515.
   PubMedGoogle Scholar
• Dangouloff T, Burghes A, Tizzano EF, et al. NBS SMA study group. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10– 12,2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020;30(1):93–103.
   PubMed Web of Science ®Google Scholar
• Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307–315.
   PubMed Web of Science ®Google Scholar
• https://www.curesma.org/wp-content/uploads/2020/11/2020_Sept-Graphic-Pipeline_v5.pdf ( Access 2020 Nov 30th)
   Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gen Ther. 2018;29(3):285–298.
   Google Scholar
• https://www.bloomberg.com/press-releases/2019-06-17/voyager-therapeutics-announces-restructured-gene-therapy-relationship-with-sanofi-genzyme-and-portfolio-update ( Access 2020 Jun 29th).
   Google Scholar
• https://xconomy.com/boston/2016/05/16/biogen-turns-to-upenn-gene-therapy-pioneers-in-wide-ranging-alliance/2/ ( Access 2020 Jun 29th).
   Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
   PubMed Web of Science ®Google Scholar
• Pane M, Coratti G, Sansone VA, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol. 2019;86(3):443–451.
   PubMed Web of Science ®Google Scholar
• Aragon-Gawinska K, Seferian AM, Daron A, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology. 2018;91(14):e1312–8.
   PubMed Web of Science ®Google Scholar
• Hagenacker T, Wurster C, Gunther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort stud. Lancet Neurol. 2020;19(4):317–325.
   PubMed Web of Science ®Google Scholar
• LoMauro A, Mastella C, Alberti K, et al. Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy. Am J Respir Crit Care Med. 2020;201(5):624–626.
   PubMed Web of Science ®Google Scholar
• De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–856.
   PubMed Web of Science ®Google Scholar
• Naryshkin NA, Weetall M, Dakka A, et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688–693.
   PubMed Web of Science ®Google Scholar
• Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501–6517.
   PubMed Web of Science ®Google Scholar
• Baranello G, Darras B, Day J, et al. Risdiplam in spinal muscular atrophy type 1. New Engl J Med. 2021 Feb 24;384(10):915–923.
   PubMedGoogle Scholar
• Konieczny P, Drosophila AR. SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. Faseb J. 2020;34(2):3021–3036.
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang JG, Liu TY, et al. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells. Biomed Pharmacother. 2017;88:708–714.
   PubMed Web of Science ®Google Scholar
• Son YS, Choi K, Lee H, et al. A SMN2 splicing modifier rescues the disease phenotypes in an in vitro human spinal muscular atrophy model. Stem Cells Dev. 2019;28(7):438–453.
   PubMed Web of Science ®Google Scholar
• Osman EY, Washington CW, Kaifer KA, et al. Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy. Ka K. 3rd Mol Ther. 2016;24:1592–1601. 9:
   PubMed Web of Science ®Google Scholar
• Sapaly D, Dos Santos M, Delers P, et al. Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy. Sci Rep. 2018;8(1):2075.
   PubMedGoogle Scholar
• Sapaly D, Delers P, Coridon J, et al. The small molecule flunarizine in spinal muscular atrophy patient fibroblasts impacts on the gemin components of the SMN complex and tdp43, an rna-binding protein relevant to motor neuron diseases. Front Mol Biosci. 2020;7:55.
   PubMed Web of Science ®Google Scholar
• Palacino J, Swalley SE, Song C, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015;11(7):511–517.
   PubMed Web of Science ®Google Scholar
• Jevtic S, Carr D, Dobrzycka-Ambrozevicz A, et al. Branaplam in type 1 spinal muscular atrophy: second part of a phase I/II study. Communication presented at 23rd SMA researcher meeting. In: Cure SMA. Anaheim, California: Disneyland hotel in; 2019 June 28–30.
   Google Scholar
• McMacken GM, Spendiff S, Whittaker RG, et al. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet. 2019;28(14):2339–2351.
   PubMed Web of Science ®Google Scholar
• Tiziano FD, Lomastro R, Abiusi E, et al. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. J Med Genet. 2019;56(5):293–300.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate is effective and safe in a phase III clinical trial in LEMS. Muscle Nerve. 2016;53(5):717–725.
   PubMed Web of Science ®Google Scholar
• Murray LM, Talbot K. Gillingwater TH review: neuro-muscular synaptic vulnerability in motor neurone disease: amyotrophiclateral sclerosis and spinal muscular atrophy. Neuropathol Appl Neurobiol. 2010;36(2):133–156.
   PubMedGoogle Scholar
• Bottai D, Adami R. Spinal muscular atrophy: new findings for an old pathology. Brain Pathol. 2013;23(6):613–622.
   PubMed Web of Science ®Google Scholar
• Goulet BB, Kothary R, Parks RJ. At the ‘junction’ of spinalmuscular atrophy pathogenesis: the role of neuromuscularjunction dysfunction in SMA disease progression. Curr Mol Med. 2013;13(7):1160–1174.
   PubMed Web of Science ®Google Scholar
• Stam M, Wadman RI, Wijngaarde CA, et al. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial). BMJ Open. 2018;8(7):e019932.
   PubMed Web of Science ®Google Scholar
• McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90.
   PubMed Web of Science ®Google Scholar
• McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;94(23):12457–12461.
   PubMed Web of Science ®Google Scholar
• Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2017;3(5):e79.
   Google Scholar
• Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682–2688.
   PubMed Web of Science ®Google Scholar
• Latres E, Pangilinan J, Miloscio L, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015;5(1):34.
   PubMedGoogle Scholar
• Long KK, O’Shea KM, Khairallah RJ, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28(7):1076–1089.
   PubMed Web of Science ®Google Scholar
• Smith RC, Cramer MS, Mitchell PJ, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14(7):1661–1670.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang X, Feng W. Reloading promotes recovery of disuse muscle loss by inhibiting TGFbeta pathway activation in rats after hind limb suspension. Am J Phys Med Rehabil. 2017;96(6):430–437.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531–543. 142;53143.
   Web of Science ®Google Scholar
• Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239–2246.
   PubMed Web of Science ®Google Scholar
• Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3(12):948–957.
   PubMed Web of Science ®Google Scholar
• Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2016;55:458–464.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23;192–201;23(1):192–201.
   Web of Science ®Google Scholar
• Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561–571.
   PubMed Web of Science ®Google Scholar
• Mariot V, Joubert R, Hourde C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8(1):1859.
   PubMedGoogle Scholar
• https://investors.scholarrock.com/events/event-details/topaz-interim-analysis-srk-015-demonstrates-clinical-proof-concept-spinal ( accessed Dec 30th 2020)
   Google Scholar
• Zhou H, Meng J, Malerba A, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle. 2020. DOI:10.1002/jcsm.12542
   Web of Science ®Google Scholar
• https://bciq.biocentury.com/products/biib110_(alg-801) accessed 30th December 2020
   Google Scholar
• Hwee DT, Kennedy AR, Hartman JJ, et al. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015;353(1):159–168.
   PubMed Web of Science ®Google Scholar
• Rudnicki SA, Andrews JA, Duong T, et al. Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study. Neurotherapeutics. 2021 Feb 23. 10.1007/s13311-020-01004-3
   PubMed Web of Science ®Google Scholar
• Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. Hepatol. 2021;74(3):560–566.
   Web of Science ®Google Scholar
• Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2020;S0022–3476(20)31466–9. 10.1016/j.jpeds.2020.11.054
   PubMed Web of Science ®Google Scholar
• Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38–43.
   PubMed Web of Science ®Google Scholar
• Seferian AM, Moraux A, Canal A, et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS One. 2015;10(4):e0121799.
   PubMed Web of Science ®Google Scholar
• Wadman RI, Van Der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;2020(1):CD006282.
   Google Scholar
• Torres-Benito L, Schneider S, Rombo R, et al. NCALD antisense oligonucleotide therapy in addition to nusinersen further ameliorates spinal muscular atrophy in mice. Am J Hum Genet. 2019;105(1):221–230.
   PubMed Web of Science ®Google Scholar